Key facts
- CyanoCapture’s last known valuation is $19.9M (Oct 2024).
- It has raised $15.6M; the latest was Early Stage VC ($10.0M) in Jun 2025.
- Notable investors include Innovate UK, University of Oxford, Desai Ventures, VKR Holding, Cartography Capital — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for CyanoCapture
- ·The full record, as it builds
Funding rounds
No funding rounds for CyanoCapture are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CyanoCapture
Developer of a carbon capture platform designed to transform CO2 emissions into high-value recombinant proteins and graphite. The company offers genetically engineered cyanobacteria, modular photobioreactor systems, and scalable biomanufacturing processes to sequester CO2 and synthesise recombinant insulin at low cost, enabling industries such as power, cement, and bioenergy to achieve cost-effective, carbon-negative production while reducing emissions.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2021
- Employees
- 14
- Website
- cyanocapture.com/
- Ownership
- Privately Held (backing)
CyanoCapture doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CyanoCapture shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CyanoCapture in its N-PORT filings yet. We sweep new filings monthly.